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Abstract 
 
Breast, ovarian, and prostate cancers are hormone-related and may have a shared genetic basis but this has 
not been investigated systematically by genome-wide association (GWA) studies.  Meta-analyses 
combining the largest GWA meta-analysis data sets for these cancers totaling 112,349 cases and 116,421 
controls of European ancestry, all together and in pairs, identified at P < 10-8 seven new cross-cancer loci: 
three associated with susceptibility to all three cancers (rs17041869/2q13/BCL2L11; 
rs7937840/11q12/INCENP; rs1469713/19p13/GATAD2A), two breast and ovarian cancer risk loci 
(rs200182588/9q31/SMC2; rs8037137/15q26/RCCD1), and two breast and prostate cancer risk loci 
(rs5013329/1p34/NSUN4; rs9375701/6q23/L3MBTL3).  Index variants in five additional regions 
previously associated with only one cancer also showed clear association with a second cancer type.  
Cell-type specific expression quantitative trait locus and enhancer-gene interaction annotations suggested 
target genes with potential cross-cancer roles at the new loci.  Pathway analysis revealed significant 
enrichment of death receptor signaling genes near loci with P < 10-5 in the three-cancer meta-analysis. 
 
Significance 
 
We demonstrate that combining large-scale genome-wide association meta-analysis findings across 
cancer types can identify completely new risk loci in common to breast, ovarian, and prostate cancer.  We 
show that the identification of such cross-cancer risk loci has the potential to shed new light on the shared 
biology underlying these hormone-related cancers. 
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Introduction 
 
Breast, ovarian and prostate cancer are hormone-related cancers (1).  Breast and ovarian cancer share 
several environmental and lifestyle risk factors that affect exogenous or endogenous estrogen exposure, 
while the androgens play a key role in the pathophysiology of prostate cancer.  Collectively, cancers at 
these three sites accounted for more than 420,000 new cases, or over 25% of all cancers diagnosed, in the 
United States in 2012 (2). 
 
All three cancers are known to aggregate in the same families (3–5).  The effects of a shared environment 
and of rare, highly penetrant alleles in established cancer predisposition genes explain only a part of the 
observed familial clustering (6).  This suggests that there exist common, low-penetrance susceptibility 
variants with shared effects across these cancer types.  Since 2007, genome-wide association studies 
(GWAS), replication studies, and a custom genotyping effort focused individually on breast, ovarian, and 
prostate cancers have identified multiple risk loci specific to each cancer (summarized in refs. (7–9)).  
The same studies have also identified three susceptibility loci where the most strongly associated single 
nucleotide polymorphism (SNP) or the index SNP exhibits pleiotropy and is common to two of the cancer 
types (10–15).  Moreover, in several other regions, separate index SNPs for risk of at least two of the 
cancers are found in close proximity and the underlying signal may well be pleiotropic (16).  However, 
genetic association studies for breast, ovarian, and prostate cancers to date have been designed to be 
cancer site-specific.  Pleiotropy between them has not itself been leveraged as the basis for systematic 
genome-wide discovery of completely new cancer risk loci – loci that share an association with at least 
two, if not all three, of the cancers. 
 
Given this background, we combined data from the largest and most recently published genome-wide 
association meta-analysis for susceptibility to breast cancer (7), ovarian cancer (8), and prostate cancer 
(9), in a single three-cancer meta-analysis of 228,770 individuals, and in pairwise combinations.  We 
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hypothesized that the substantial gain in power afforded by the cross-cancer meta-analyses would enable 
the identification, at genome-wide significance, of risk loci sharing an association with more than one of 
the three cancers that are novel for each of the cancers (17).  Pleiotropic alleles at these loci may be 
modestly associated with each of the cancers and not previously detected at the standard threshold for 
genome-wide significance (P < 5 x 10-8) in single-cancer studies due to sample size constraints.  We also 
investigated whether the index SNP in regions so far known to contain associations with only one cancer 
out of breast, ovarian, or prostate cancer showed clear evidence for association with another cancer out of 
the three.  Further, at the rare variant end of the genetic association spectrum, the identification of rare 
alleles that confer inherited susceptibility to multiple cancers in genes such as BRCA1, BRCA2, and TP53 
has yielded critical insights into their role in cancer etiology (18,19).  Motivated by this observation, we 
annotated the new cross-cancer risk loci using cell-type specific expression quantitative trait locus 
(eQTL) and enhancer-gene interaction maps, and performed enrichment analysis for molecular pathways 
in the top regions spanning breast, ovarian, and prostate cancer to identify putative shared target genes 
and mechanisms potentially driving common genetic susceptibility across these hormone-related cancers. 
 
Results 
 
Study Populations  
 
We used summary statistics for association with cancer risk from the largest and most recently published 
meta-analysis of GWA, replication and custom genotyping case-control studies for each cancer (7–9).  
These meta-analyses included 62,533 women with breast cancer (including 12,412 women with estrogen 
receptor (ER)-negative tumors) and 60,976 controls, 15,437 women with invasive epithelial ovarian 
cancer (including 9,627 women with serous tumors) and 30,845 controls, and 34,379 men with prostate 
cancer and 33,164 controls.  All individuals were of European ancestry and a total of 8,564 controls 
overlapped between the breast and ovarian cancer studies.  The summary statistics were available for 
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variants with minor allele frequency (MAF) > 0.5% that had either been genotyped or imputed 
independently in the breast, ovarian and prostate cancer studies using the 1000 Genomes Project (March 
2012 release) European reference panel. 
 
New Associations with a Second Cancer at Known Single-cancer Risk Loci 
 
We listed the published index SNP at each of the 92, 18 and 100 loci known to be associated with breast, 
ovarian and prostate cancer susceptibility, respectively, in European-ancestry populations (Supplementary 
Table S1).  The list comprised 207 unique SNPs after accounting for the three SNPs that were each an 
index SNP for two cancers (rs10069690 at 5p15 and rs8170 at 19p13 for breast and ovarian cancer, and 
rs4245739 at 1q32 for breast and prostate cancer; refs. (10–15)).  Separate index SNPs for two of the 
cancers were within 1 Mb of each other in 21 genomic regions, including two regions (at 6p22 and 8q24) 
that contained index SNPs for all three cancers (Supplementary Table S2). 
 
Scanning for these 207 SNPs using the summary data identified novel associations with breast cancer 
susceptibility at the ovarian cancer index SNP rs635634 at 9q34/ABO (PBrCa = 8.1 x 10-7) and at the 
prostate cancer index SNPs rs6763931 at 3q23/ZBTB38 (PBrCa = 1.2 x 10-6) and rs11214775 at 
11q23/HTR3B (PBrCa = 5.2 x 10-5) with consistent direction of allelic effect between the previously 
reported and novel associations across cancer types (Table 1).  Further, the risk (T) allele of the breast 
cancer index variant in BRCA2, rs11571833 (MAF = 0.8%), was associated with ovarian cancer risk 
(POvCa = 6.4 x 10-8 for serous invasive ovarian cancer; odds ratios and additional details in Table 1) while 
the protective (T) allele of the breast cancer index SNP rs1830298 at 2q33/ALS2CR12 was associated 
with prostate cancer risk (PPrCa = 1.3 x 10-6; Table 1).  Thus, index SNPs at five loci so far known to be 
associated with only one cancer type demonstrated strong evidence for association with a second cancer 
type, out of breast, ovarian, and prostate cancer, at a significance level of 6 x 10-5 after Bonferroni 
correction for testing 207 SNPs in four ways (breast and ovarian cancer, breast and prostate cancer, 
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ovarian and prostate cancer, and ER-negative breast and serous ovarian cancer).  There was no known 
index SNP associated with the second cancer type within 1 Mb on either side of any of the new signals. 
 
Meta-analysis of Breast, Ovarian and Prostate Cancer Genome-wide Association Meta-analysis Data 
 
Having examined the index SNPs at established risk loci for each cancer to uncover new cross-cancer 
association signals, we conducted a fixed-effects meta-analysis using the breast, ovarian and prostate 
cancer summary statistics for all variants that were nominally associated (P < 0.05) with each of the three 
cancers.  In effect, our study design enabled independent replication of findings reaching P < 0.05 for 
association with susceptibility to one cancer type in data from the two other cancer types.  We reasoned 
that this approach could identify previously unrecognized cancer risk loci that were shared by breast, 
ovarian and prostate cancer and achieved genome-wide significance only after combining data from the 
three cancers. 
 
The meta-analysis identified 267 alleles spanning 18 independent loci that were associated at P < 10-8 
with breast, ovarian and prostate cancer susceptibility with the same direction of effect across all three 
cancers (Manhattan plot in Figure 1; Supplementary Table S3).  The threshold for genome-wide 
significance was set at a more stringent P < 10-8 compared to the standard P < 5 x 10-8 to correct for 
multiple comparisons arising from the fact that we searched for associations shared between cancer types 
in five possible ways (breast, ovarian and prostate cancer, breast and ovarian cancer, breast and prostate 
cancer, ovarian and prostate cancer, and ER-negative breast and serous ovarian cancer; the pairwise 
searches are described in the next section).  Moreover, it is possible to obtain a genome-wide significant 
signal in a meta-analysis of three cancers in the setting of a particularly strong association between a 
variant and a subset of one or two of the cancers and no association with the remaining cancer(s).  We 
addressed this possibility by applying the association analysis based on subsets (ASSET; ref. (20)) 
method to test whether the best association model for each newly identified index variant involved all 
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three cancers, as would be expected for true cross-cancer signals.  Model selection using ASSET 
demonstrated that all three cancers contributed to the signal at the most significantly associated variant at 
13 of the 18 loci (Supplementary Table S3, ASSET column).  None of these 13 index variants showed 
significant heterogeneity in the per-allele odds ratio between the three cancers further confirming 
consistent pan-cancer effects (Cochran’s Q-test for heterogeneity, Phet > 0.05). 
 
To account for correlation between the breast and ovarian cancer studies due to the 8,564 controls shared 
between them, we repeated the meta-analysis for the 13 index variants using a statistical adjustment for 
studies with overlapping controls that required only summary statistics and exact sample counts 
contributing to the association at each variant from the corresponding data sets (21).  Two of the variants 
fell just short while 11 remained at P < 10-8 after this adjustment (Supplementary Table S3, Padjusted 
column).  Eight of these 11 loci were less than 1 Mb from a known index SNP for at least one of the three 
cancers.  Details of the eight susceptibility loci including linkage disequilibrium (LD) information with 
respect to known index SNPs are also presented in Supplementary Table S3. 
 
The three remaining loci were over 1 Mb away from known index SNPs for any of the three cancers and 
indexed by the variants rs17041869 (in BCL2L11 at 2q13; Pmeta = 5.1 x 10-9; Table 2A), rs7937840 (in 
INCENP at 11q12; Pmeta = 5.0 x 10-9), and rs1469713 (in GATAD2A at 19p13; Pmeta = 3.4 x 10-10).  They 
represent entirely new association signals for all three cancers discovered at genome-wide significance (P 
< 10-8) by leveraging the shared genetic architecture of breast, ovarian and prostate cancer (P-values for 
each cancer type in Table 2A; regional association plots in Supplementary Fig. S1A-C).  While the newly 
identified index variant rs1469713 itself was 960 kb from a known breast cancer index SNP rs4808801, 
42 of the 89 variants in the new 19p13/GATAD2A region that were correlated with rs1469713 and reached 
P < 10-8 in the three-cancer meta-analysis were between 1 to 1.2 Mb away from rs4808801 
(Supplementary Fig. S1C).  Furthermore, rs1469713 and rs4808801 were not linked (r2 = 0.001 in the 
European populations from the 1000 Genomes Project) and the association at rs1469713 remained on 
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analysis of the breast cancer data conditioning on rs4808801, confirming independence of the new signal 
from the known one (Supplementary Table S4, which includes three-cancer meta-analysis results for 
rs1469713 undertaken using results from the conditional analysis).  We also confirmed that the three new 
index SNPs were not correlated with known breast, ovarian or prostate cancer index SNPs up to 10 Mb 
away on either side (r2 < 0.01 in 1000 Genomes European populations).  Figure 2A shows forest plots of 
odds ratios and 95% confidence intervals corresponding to association of the three novel index variants 
with each cancer separately and on meta-analysis.  While rs17041869 had been genotyped, the two other 
index variants had been imputed with accuracy, r2 ≥ 0.89 (Table 2A). 
 
Pairwise Meta-analyses using the Breast, Ovarian and Prostate Cancer Data 
 
To identify new risk loci in common specifically to two of the three cancers, we combined data from the 
three cancer types in pairs using fixed-effects meta-analyses.  We also conducted an additional meta-
analysis for shared susceptibility to ER-negative breast and serous ovarian cancer as the two previously 
reported index SNPs known to be shared between breast cancer and ovarian cancer are specific to these 
two subtypes (rs10069690 and rs8170 (10–13)).  Before examining results from each pairwise meta-
analysis, we excluded all variants within 1 Mb of known index SNPs for either or both cancer types 
contributing to the meta-analysis to avoid detecting signals unduly driven by established associations in 
one or both cancer types contributing to the meta-analysis.  We identified new shared associations with 
breast and ovarian cancer risk at rs200182588 (in SMC2 at 9q31; Pmeta = 8.9 x 10-9 after adjusting for 
overlapping controls) and rs8037137 (near RCCD1 at 15q26; Pmeta = 9.1 x 10-10 after adjustment), and 
with breast and prostate cancer risk at rs5013329 (in NSUN4 at 1p34; Pmeta = 1.8 x 10-11) and rs9375701 
(in L3MBTL3 at 6q23; Pmeta = 3.4 x 10-10).  Full results for the four new index SNPs are presented in 
Table 2B, forest plots in Figure 2B, and regional association plots in Supplementary Fig. 1D-G.  These 
SNPs were not correlated with known index SNPs for the corresponding individual cancer types up to 10 
Mb away on either side (r2 < 0.01 in 1000 Genomes European populations).  ASSET confirmed 
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contributions from both cancer types to each new signal, none of them displayed significant heterogeneity 
in the per-allele odds ratio (Phet > 0.05), and the index variants had been imputed with accuracy, r2 ≥ 0.81 
(Table 2B).  No new locus was identified at genome-wide significance (P < 10-8) in the ovarian and 
prostate cancer and in the subtype-specific ER-negative breast and serous ovarian cancer meta-analyses 
after excluding all variants within 1 Mb of known index SNPs for either or both cancer types contributing 
to the corresponding meta-analyses. 
 
Further, there is some evidence that alleles that increase risk of one cancer confer protection from another 
cancer (notably at rs4245739 which is a known index SNP for both breast and prostate cancer). Therefore, 
we used the two-sided subset function implemented in ASSET to also look for alleles in the three-cancer 
meta-analysis that were associated with all three cancers (with a combined ASSET P < 10-8) but where 
the direction of allelic effect on one of the cancers was opposite to that observed for the other cancer 
types (details in Methods).  To search for such alleles in each pairwise meta-analysis, we reversed the 
signs on the effect size estimates in one of the two data sets and repeated fixed-effects meta-analysis (22).  
However, no novel loci were identified at P < 10-8 in the search for shared alleles with opposite effects on 
risk of different cancer types out of the three cancers using either approach. 
 
Of the seven new loci identified by the three-cancer and pairwise meta-analyses, the index SNP at 2q13 is 
a genotyped SNP while the index SNPs at the remaining loci were well imputed with accuracy, r2 ≥ 0.81 
and had MAF ≥ 12%.  Imputation was conducted independently for data from each cancer type and 
imputation accuracy estimates were consistent across cancer types.  In each of the three single-cancer 
genome-wide association meta-analyses that contributed to this three-cancer study, we have demonstrated 
high concordance between imputed and genotyped SNP results for common SNPs (MAF > 5%) identified 
at standard genome-wide significance (P < 5 x 10-8) that have imputation accuracy > 0.80.  Finally, for 
four of the six new loci where the index SNP was an imputed SNP, we were also able to identify a 
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genotyped SNP in the same region that was also genome-wide significant (P < 10-8; Supplementary Table 
S5 provides results for the most significantly associated genotyped SNP at each of these six loci). 
 
Expression QTL Analyses Suggest Target Genes Shared Across Relevant Cell Types at New Loci 
 
We carried out cis-expression quantitative trait locus (eQTL) analyses for the seven new index variants 
(listed in Table 2) and all genes up to 1 Mb on either side of each variant using breast (n = 183), ovarian 
(n = 85), and prostate (n = 87) normal tissue samples from the Genotype-Tissue Expression (GTEx) 
Project (23).  The risk (T) allele of the breast and prostate cancer index variant rs9375701 was 
significantly associated with reduced expression of L3MBTL3 in both breast (P = 3.5 x 10-9) and prostate 
(P = 8.9 x 10-7) tissue (box plots in Supplementary Fig. S2A).  There were no significant associations (P < 
0.05) between this SNP and the expression level of any other gene in the same region in either cell type.  
A consistent cross-cell type association was also observed between the risk (T) allele of the breast and 
ovarian cancer index variant rs8037137 and decreased expression of RCCD1 in both breast (P = 1.1 x 10-
15) and ovarian (P = 1.1 x 10-5) tissue (box plots in Supplementary Fig. S2B).  Some of the index variants 
also yielded eQTL associations that were nominally significant in only one of the three cell types (full 
results in Supplementary Table S6).  Further, we looked up two of the seven index variants that were 
reported in a large database of eQTLs from peripheral blood samples (n = 5,311; ref. (24)) and found an 
association between the risk (G) allele of the three-cancer index SNP rs1469713 and increased expression 
of GATAD2A (P = 9.8 x 10-198) and replicated the association between the T allele of rs9375701 and 
decreased expression of L3MBTL3 (P = 4.7 x 10-125). 
 
Cell-type Specific Enhancer Maps Suggest Target Genes Shared Across Relevant Cell Types at New Loci 
 
Expression QTL analysis may not always be able to detect functionally important variant-gene 
relationships over background noise given small sample sizes of eQTL data sets, the dynamic nature of 
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gene expression, and the likely modest biological effects of risk variants (25).  Disease-associated genetic 
variation has been found enriched in cell-type specific enhancer elements.  Therefore, as an alternative 
strategy to identify potential cross-cancer susceptibility genes, we annotated all variants with P < 10-8 at 
the seven new loci (variant counts in Table 2) using maps of enhancers in breast, ovarian and prostate cell 
types (26–28).  We intersected these maps with computationally predicted enhancer-gene interactions in 
the same cell types (26–28) as well as experimentally derived interactions that were only available for 
breast cells (HMEC and MCF7 profiled using Hi-C and ChIA-PET, respectively; refs. (29,30)). 
 
Two intronic SNPs in GATAD2A out of the 89 variants with P < 10-8 at the 19p13 three-cancer risk locus 
(rs2916068 and rs2965183; Figure 3; Supplementary Table S7) were located in enhancers in normal and 
cancerous breast (HMEC and MCF7, respectively), normal ovarian (ovary, UCSD) and prostate cancer 
(LNCaP) cells and in each instance, this enhancer was predicted to interact with GATAD2A.  A direct 
physical interaction between rs2916068 and the GATAD2A promoter was additionally confirmed in the 
MCF7 breast cancer cells assayed by ChIA-PET.  The index SNP rs17041869 at the 2q13 three-cancer 
risk locus mapped to an enhancer in breast (MCF7) and prostate (LNCaP) cancer cells and in both cases, 
this enhancer was predicted to interact with BCL2L11 (Figure 4; Supplementary Table S7).  Notably, 
while evidence for BCL2L11 as a target gene was not found in ovarian cells by enhancer-gene interaction 
annotation, the eQTL analysis did show a marginally significant association between the risk-conferring 
(G) allele of rs17041869 and elevated expression of BCL2L11 in normal ovarian tissue samples 
(Povary_eQTL= 0.048), this being the only significant cis-association detected for rs17041869 in any of the 
three cell types (Supplementary Table S6). 
 
At the 1p34 breast and prostate cancer region, several of the 218 P < 10-8 variants overlapped enhancers 
that interacted with NSUN4 in breast (MCF7; interaction confirmed by ChIA-PET) and prostate (LNCaP) 
cancer cells (Supplementary Table S7).  SNP rs17361950 intersected enhancers interacting with FAAH in 
MCF7 (confirmed by ChIA-PET) and LNCaP while the indels chr1:46505589:I and chr1:46505785:I 
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intersected enhancers targeting PIK3R3 in LNCaP and in the breast cancer cell line HCC1954 
(Supplementary Table S7).  The risk (T) allele of the index SNP rs5013329 at the same locus was 
significantly associated with lower expression of NSUN4 in breast (Pbreast_eQTL = 0.001) and the long non-
coding RNA (lncRNA) gene RPS15AP10 in prostate (Pprostate_eQTL = 0.02) normal tissues (Supplementary 
Table S6).  These findings collectively implicate NSUN4 as the strongest shared functional candidate at 
1p34.  In addition to eQTL and enhancer mapping, we also annotated P < 10-8 variants in the seven 
regions using the HaploReg (31), lncRNASNP (32), and PolymiRTS (microRNA and miRNA target 
region annotation; ref. (33)) databases (Supplementary Table S8). 
 
Pathway Analysis Implicates Apoptosis as a Potential Mechanism for Susceptibility to All Three Cancers 
 
Finally, we used pathway analysis to explore the genome-wide significant regions and the fraction of 
associations just failing to reach this threshold in the meta-analysis of data from the three cancers.  We 
took all alleles (regardless of proximity to known index SNPs for any of the three cancers) that met three 
criteria: (i) P < 10-5 in the three-cancer meta-analysis, (ii) same direction of effect across all three cancers, 
and (iii) no significant heterogeneity in the per-allele odds ratio between cancers (Phet > 0.05).   These 884 
alleles were then subjected to LD-based ‘pruning’ to leave 69 independent alleles (details in Methods).  
Taking regions up to 1 Mb on either side of the 69 alleles and merging overlapping regions yielded 51 
intervals harboring a shared association with breast, ovarian and prostate cancer at P < 10-5.  We used the 
Interval Enrichment tool (INRICH; ref. (34)) to permute 5,000 matched intervals and tested for 
enrichment of pathways from four databases (KEGG, Biocarta, Reactome, and Gene Ontology), 
correcting for multiple comparisons separately in each database.  Only one pathway, from Biocarta, 
survived this correction: 8/32 genes from the induction of apoptosis through DR3 and DR4/5 Death 
Receptors signaling pathway (CASP9, LMNA, CASP7, TNFSF10, TNFRSF10A, TNFRSF10B, RELA, and 
FADD; ref. (35)) were located in 7/51 intervals (INRICH analysis Pempirical = 0.0004, Pcorrected = 0.01; top 
SNP in each interval listed in Supplementary Table S9).  BCL2L11 – the likely target of the new 2q13 
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three-cancer risk locus – is not a member of this pathway but given that this gene is a known apoptosis 
facilitator (36,37), we also checked for and found interactions between BCL2L11 and several members of 
the Biocarta Death Receptor signaling pathway (Supplementary Fig. S3; details in Methods).  Moreover, 
other apoptosis-related pathways that did contain BCL2L11 were among the top pathways in the 
Reactome and Gene Ontology databases (Pempirical = 0.04—0.006; Supplementary Table S10). 
 
Discussion 
 
Here we report findings from the first cross-cancer type genome-wide association meta-analysis focused 
on three hormone-related cancers.  Performing a series of fixed-effects meta-analyses to cover all possible 
combinations of these three cancers, and a subtype-specific analysis for ER-negative breast and serous 
ovarian cancers, we identified three loci demonstrating shared association with breast, ovarian, and 
prostate cancer risk, two with breast and ovarian cancer risk, and two with breast and prostate cancer risk.  
Each of these seven loci was over 1 Mb away from previously identified risk loci and had the same 
direction of allelic effect for the corresponding individual cancer types. They were followed up using cell-
type specific eQTL and enhancer data to identify the gene(s) likely to be targeted by the risk variants that 
are in common across cell types.  Although we prioritized discovery of cross-cancer risk loci that were 
novel for each of the cancers, we also found that the index SNP in five additional regions previously 
known to be associated with only one of the three cancers showed robust evidence for pleiotropic 
association with a second cancer type out of the three.  Only one of these five showed opposite effects on 
the risk of two cancer types (rs1830298, a known breast cancer index SNP at 2q33, found to be associated 
with prostate cancer) possibly reflecting tissue-specific regulatory mechanisms and/or tissue-specific 
modulation by environmental factors at this locus. 
 
Annotation of the new 19p13 three-cancer susceptibility locus revealed that two strongly associated 
variants (P < 10-8) intersected overlapping enhancer elements interacting with GATAD2A in breast, 
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ovarian, and prostate cell types.  GATAD2A is a subunit of the nucleosome remodeling and histone 
deacetylase (NuRD) complex, a chromatin-level regulator of transcription with a number of important and 
emerging roles in cancer biology (38).  At the level of transcription, the NuRD complex is recruited by 
tissue-specific oncogenic transcription factors to repress the expression of tumor suppressor genes while 
at the post-translational level, this complex has been shown to deacetylate p53 to inactivate p53-induced 
apoptosis.  The index variant at the 2q13 three-cancer risk locus was located in enhancers targeting the 
apoptosis facilitator BCL2L11 in breast and prostate cancers cells and was associated with expression of 
the same gene in normal ovarian cells (36,37).  Interestingly, this variant rs17041869 is 53 kb away from 
rs6738028, a genome-wide significant index SNP for serum dehydroepiandrosterone sulphate (DHEAS) 
concentrations (39).  Correlation between the two variants was r2 = 0.08 and D’ = 1, with the cancer risk-
conferring G allele (frequency = 0.10) of rs17041869 always segregating with the C allele (frequency = 
0.59) of rs6738028 in 1000 Genomes European populations (although we did not find rs6738028 itself to 
be associated with cancer risk).  Secreted largely by the adrenal glands, DHEAS is the most abundant 
circulating steroid in the human body and is converted into active androgens and estrogen in the relevant 
peripheral tissue (40,41).  DHEAS levels have previously been linked to increased risk of breast cancer 
but the direction of its associations with cancers of the prostate and ovary are less clear (42–44).  The 
DHEAS GWAS also showed that the C allele of rs6738028 was associated with higher DHEAS levels 
and significantly lower expression of BCL2L11 in blood and adipose tissue, in keeping with the anti- and 
pro-apoptotic roles of DHEAS and BCL2L11 (45,46), respectively.  Taken together, these observations 
suggest that though independent variants may underlie the DHEAS and hormone-related cancer 
susceptibility signals at 2q13, the effects of both may be regulated through BCL2L11.  While we were 
unable to highlight a particular target gene at the 11q12 three-cancer risk locus, the index variant and 
many linked SNPs lie in INCENP (Supplementary Fig. S1B) and the locus also includes MTA2 (467 kb 
from the index variant), another member of the NuRD complex (38).  INCENP codes for the inner 
centromere protein, a non-enzymatic subunit of the chromosomal passenger complex (CPC; ref. (47)), 
that serves as the scaffold for CPC assembly (48).  The CPC is a master regulator of mitosis and the inner 
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centromere protein is essential for the activation and cellular localization of the enzymatic subunit of the 
CPC, Aurora B kinase (49), which is a much-studied target with roles in multiple cancers (50).  We have 
previously identified association between other correlated variants in INCENP and breast cancer 
susceptibility in a candidate gene study of CPC components though these associations did not reach 
genome-wide significance (51), further underscoring the utility of combining data across cancers to pick 
up far more robust signals. 
 
Quantitative trait locus analysis identified a highly significant and directionally consistent cross-tissue 
association with L3MBTL3 expression for the 6q23 breast and prostate cancer index SNP.  L3MBTL3 is a 
member of the malignant brain tumor (MBT) family of chromatin-modifying transcriptional repressors 
with histone code reading functions (52).  Similarly, the eQTL data strongly suggested that RCCD1 was a 
shared cancer susceptibility gene at the 15q26 breast and ovarian cancer risk locus.  It is worth noting that 
the index variant at this locus, rs8037137, is correlated with rs2290203 (r2 = 0.6, D’ = 1 in 1000 Genomes 
European populations), which is a genome-wide significant index SNP for breast cancer predisposition in 
East Asians (Prs2290203 = 1.8 x 10-6 in our breast-ovarian meta-analysis with same direction of effect as the 
East Asian breast cancer-specific signal; ref. (53)).  SNPs in this region have not previously been 
associated with breast cancer risk in Europeans or with ovarian cancer risk in any population.  EQTL 
analysis in the East Asian study also identified the poorly characterized RCCD1 as the likely target gene 
of the locus.  A combination of enhancer and eQTL mapping implicated NSUN4 as a potential breast and 
prostate cancer risk gene at 1p34.  NSUN4 encodes a methyltransferase with an important role in 
mitochondrial ribosome production (54).  The index variant (rs200182588) at the 9q31 breast and ovarian 
cancer susceptibility locus lies in the 5’-untranslated region of SMC2 and binds several transcription 
factors in diverse tissue types including c-Myc in MCF7 cells (Supplementary Table S8).  The structural 
maintenance of chromosomes protein-2 encoded by SMC2 is a core component of the condensin complex 
that is responsible for close packaging of chromatin before cell division (55).  Moreover, SMC2 is a direct 
transcriptional target of oncogenic WNT signaling and N-Myc (56,57), and is emerging as a critical 
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player in the DNA damage response (58).  The index risk SNP at one of the seven new cross-cancer 
susceptibility loci discussed here was a genotyped SNP while at four other loci we were able to identify a 
genotyped SNP in the same region that was also genome-wide significant at P < 10-8.  For the two 
remaining loci (9q31 and 11q12), the index SNPs were imputed SNPs (imputation accuracy > 0.8) and 
should be followed-up with confirmatory genotyping in additional samples. 
 
Pathway analysis indicated significant involvement of induction of apoptosis through DR3 and DR4/5 
death receptor (DR) signaling in mediating global susceptibility to these three hormone-related cancers 
(35).  In particular, our analysis revealed that 1 Mb windows around two SNPs on chromosomes 3 and 8 
associated just short of genome-wide significance in the three-cancer meta-analysis (Prs3819772 = 7.6 x 10-8 
and Prs10113131 = 9.5 x 10-7; Supplementary Table S9), harbored TNFSF10 that codes for the TNF-related 
apoptosis-inducing ligand (TRAIL) and TNFRSF10A and TNFRSF10B that encode the two receptors of 
TRAIL, DR4 and DR5, respectively.  DR5 expression in prostate cancer cells is androgen dependent and 
elevated levels of androgens have been shown to inhibit TRAIL-induced apoptosis in LNCaP (59).  
Likewise, most breast and ovarian cancer cell lines are resistant to TRAIL-induced apoptosis (60,61), 
likely due to estrogenic regulation of death receptor signals (62), endocytosis of cell surface DR4 and 
DR5 in breast cancer (63), and aberrant cleavage of the caspases in ovarian cancer (61).  Given that 
recombinant TRAIL and its receptor agonist antibodies are already under development (64,65), the 
possible contribution of this druggable pathway to the risk of multiple hormone-related cancers might 
offer new avenues for early-stage cancer therapy. 
 
In conclusion, we have demonstrated that pleiotropy or association of the same variant with multiple 
phenotypes, a genetic phenomenon recognized as early as Mendel’s classic 1866 paper (66), can be 
tapped to combine genome-wide association data across cancer types and uncover several risk loci that 
are shared by – and represent novel findings for – breast, ovarian, and prostate cancer.  Our preliminary in 
silico characterization of the new loci also suggests that the integration of orthogonal resources such as 
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eQTL and enhancer annotations from different cell types enabled by cross-cancer site strategies may 
refine the post-GWAS identification of putative functional target genes at cancer risk loci (67).  Finally, 
the increased power of pleiotropy-informed locus discovery, fine mapping, pathway analysis, and 
polygenic risk prediction over conventional single-cancer approaches has the potential to offer fresh 
insights into the common biology that may underpin susceptibility to these three hormone-related cancers, 
with implications for cross-cancer genetic screening (68).  This work thus illustrates the need for even 
larger pan-cancer genome-wide association meta-analyses that include data from a broad range of cancer 
types including the other hormone-related cancers. 
 
Methods 
 
Breast, Ovarian and Prostate Cancer Data Sets 
 
The data sets contained SNP-level summary statistics from association analyses for cancer risk from a 
published meta-analysis of genome-wide association study (GWAS) discovery, replication, and custom 
genotyping case-control studies for each cancer.  The relevant local institutional review board approved 
each of these studies, informed consent was obtained from participants, and the studies were conducted in 
accordance with the Declaration of Helsinki.  Details of the study participants, genotyping, quality 
control, imputation, association analysis and meta-analysis for each data set have been previously 
described (7–9).  All analyses in the current study were restricted to data from individuals of European 
ancestry.  Genotypes in each data set had been imputed into the March 2012 release of the 1000 Genomes 
Project European ancestry reference panel (version 3 of the Phase 1 integrated variant set release; ref. 
(69)).  We only considered results for variants imputed with imputation accuracy, r2 > 0.3.  Imputation 
accuracy estimates were calculated in samples from the Collaborative Oncological Gene-Environment 
Study (COGS; ref. (70)) since they comprised the largest subset of each data set.  In addition to summary 
statistics for association with susceptibility to overall breast cancer, all invasive epithelial ovarian cancer, 
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and overall prostate cancer, we also used summary results for association with estrogen receptor-negative 
breast cancer and serous epithelial ovarian cancer risks. 
 
Compilation of the list of published breast, ovarian, and prostate cancer index SNPs is described under 
Supplementary Methods. 
 
Meta-analysis 
 
Estimated magnitudes of association (beta coefficients) and standard errors for variants from each data set 
were combined assuming fixed effects using inverse-variance weighted meta-analysis implemented in 
METAL (71).  Heterogeneity in the per-allele odds ratio between cancers was assessed using P-values 
from Cochran’s Q-statistic also calculated by METAL.  All linkage disequilibrium (LD) calculations (r2 
and D’) presented were performed using the LDlink suite and data from the 1000 Genomes Project 
European ancestry populations (69,72). 
 
Alleles with Opposite Effects and Contribution of Each Data Set to Association Signals 
 
To identify alleles that confer risk of one cancer but are protective for another cancer in each two-cancer 
meta-analysis, we reversed the signs on the beta coefficients in one of the two data sets and repeated the 
corresponding meta-analysis as done previously by Zhernakova et al. (ref. (22)).  To identify alleles 
sharing associations with breast, ovarian, and prostate cancer risk where the direction of allelic effect on 
any one of these cancers was opposite to that observed for the other two, we used the two-sided subset 
search function in the association analysis based on subsets (ASSET) R package (version 1.0.0) (20).  
Specifically, we used the h.traits function with arguments set as follows: side=2, meth.pval=c(“DLM”), 
and search=2.  This function in ASSET searches for such alleles for subsets of data sets (in this case 
representing phenotypes or cancers) and calculates fixed-effects meta-analysis-style test statistics 
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separately for each subset (that is, for two cancers in one direction and the third cancer in the opposite 
direction).  The two test statistics are then combined using a Chi-squared statistic and corrected for the 
multiple subset searches conducted.  We also used the model-selection function in ASSET to identify the 
subset of data sets or cancer types in each meta-analysis that contributed to the overall association signal 
at the newly identified index variants. 
 
Overlapping Controls Between the Breast and Ovarian Cancer Studies 
 
An overlap of 8,548 controls existed between the breast and ovarian cancer data sets.  To account for 
correlation between the data sets due to overlapping controls, we applied a general statistical decoupling 
framework that involves adjusting the standard errors of each variant from the dependent data sets using a 
correlation matrix generated from the sample overlap counts (21).  The data sets can then be analyzed as 
independent data sets.  The correlation matrix itself was calculated as previously described (73).  
Correlations between the overall breast and all invasive epithelial ovarian cancer data sets and between 
the ER-negative breast and serous ovarian cancer data sets were found to be ~8% and ~4%, respectively.  
We applied the decoupling framework using exact counts for samples contributing to the association at 
the index variant in each new region identified at P < 10-8 in any meta-analysis involving both the breast 
and ovarian cancer studies and repeated the corresponding meta-analysis using METAL to confirm the 
signal for the variant after adjustment of standard errors. 
 
Expression QTL Analyses 
 
Expression QTL analysis results for each index variant at the seven loci listed in Table 2 and all genes 
within 1 Mb of it were looked up using the Genotype-Tissue Expression (GTEx) project Portal in normal 
breast (n = 183), ovarian (n = 85), and prostate (n = 87) tissue samples (23).  To improve the power to 
detect significant eQTLs, at the cost of losing tissue-specificity, we also performed the same searches 
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(where data availability permitted) in the blood eQTL browser that is based on eQTL analysis in 
peripheral blood samples from 5,311 individuals (24). 
 
Enhancer-Gene Interactions 
 
Maps of enhancer regions with predicted target genes were obtained from Hnisz et al. (26), Corradin et al. 
(28), and He et al (27).  Enhancers active in the breast cell types HMEC (normal), MCF-7 (cancer), and 
HCC1954 (cancer), normal ovarian cell types from UCSD, and the prostate cancer cell line LNCaP (as 
relevant to each locus) were intersected with all variants with P < 10-8 in the seven regions listed in Table 
2 using Galaxy.  ENCODE Chromatin Interaction Analysis by Paired-End Tag sequencing (ChIA-PET) 
data from MCF-7 cells (mediated by RNA polymerase 2 and ERα) were downloaded using the UCSC 
Table browser (30).  Galaxy was used to identify the ChIA-PET interactions between an implicated breast 
cell enhancer (containing a strongly associated variant) and a predicted gene promoter (defined as regions 
3 kb upstream and 1 kb downstream of the transcription start site). 
 
Functional Annotation 
 
We annotated all variants with P < 10-8 at the seven loci listed in Table 2 using the HaploReg v3 pipeline 
(31).  Variants were annotated with (a) their location within a gene or distance from the nearest gene, (b) 
their functional consequence as per dbSNP if they were intragenic (intronic; located in the 3’- or 5’-
untranslated region; exonic: synonymous or nonsynonymous), (c) GERP and SiPhy conservation scores 
(74,75), (d) effect on regulatory (transcription factor binding) motifs calculated using position weight 
matrices obtained from TRANSFAC (76), JASPAR (77), and other sources(78), and (e) transcription 
factor binding data from ENCODE (78).  We also annotated these SNPs based on whether they were 
located in long non-coding RNAs and microRNAs or microRNA seed regions and target sites (32,33).  
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Regional association plots that integrated 1000 Genomes LD data with gene annotation tracks were 
generated using LocusZoom (79). 
 
LD-based Pruning and Pathway Analysis 
 
All (884) alleles demonstrating the same direction of effect across cancers without significant 
heterogeneity in the per-allele odds ratio (Phet > 0.05) and with association P-values < 10-5 in the meta-
analysis of the three cancers were subjected to LD-based ‘pruning’ (80).  Starting with the most 
significantly associated variant, all variants within 1 Mb of it with correlation, r2 > 0.1 (calculated using 
1000 Genomes Project European population genotype data) were removed.  This was followed by a 
second round of LD-pruning with the same r2 threshold but for a distance of 10 Mb to remove variants in 
long-range LD.  This yielded 69 independent variants.  Assuming that a variant could potentially regulate 
any gene up to 1 Mb on either side of it (81), we generated 69 2-Mb-wide intervals such that each was 
centered on one variant.  Merging overlapping intervals left 51 intervals. 
 
The Interval Enrichment (INRICH; ref. (34)) tool was used to permute 5,000 sets of intervals with each 
set reasonably well-matched to the original set of 51 intervals in terms of interval size, number of genes 
and variants per interval, and variant positions (sampled based on hg19 gene and 1000 Genomes variant 
location data).  The permuted sets were used to calculate an empirical P-value for enrichment of genes 
from a particular pathway among the observed intervals.  A second permutation step (1,000 permutations) 
was applied to correct for multiple comparisons at the pathway level.  All pathways containing between 
20 and 200 genes from four extensively-curated online pathway repositories: Biocarta, the Kyoto 
Encyclopedia of Genes and Genomes (KEGG), Reactome, and Gene Ontology were obtained from the 
Molecular Signatures Database (MSigDB v3.0; (82)).  Four pathway databases were used because each 
has a distinct and largely complementary approach to capturing known biological pathways (83).  
However, considerable overlap was present in gene content of the common pathways across databases 
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and therefore we applied INRICH separately to pathways from each database.  The different types of 
biological interactions shown in Supplementary Figure 3 between BCL2L11 and the genes in the Biocarta 
induction of apoptosis through DR3 and DR4/5 Death Receptors pathway were identified using the 
GeneMania server (84). 
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Table 1. New associations with a second cancer at known single-cancer risk locia 
Region, Index SNP, Alleles (E/R),       Imputation 
positionb nearest gene EAF Cancer Type OR (95% CI) P r2c 
New associations with breast cancer at known index SNPs 
for ovarian or prostate cancer (same direction) 
       
9q34 rs635634 T/C Breast cancer 1.06 (1.03-1.08) 8.1x10-7 0.88 
136155000 ABO 0.20 Ovarian cancer 1.12 (1.07-1.16) 8.6x10-9 0.88 
       
3q23 rs6763931d A/G Breast cancer 1.04 (1.02-1.06) 1.2x10-6 1f 
141102833 ZBTB38 0.45 Prostate cancer 1.06 (1.03-1.08) 1.0x10-6 1f 
       
11q23 rs11214775 A/G Breast cancer 0.96 (0.94-0.98) 5.2x10-5 0.82 
113807181 HTR3B 0.29 Prostate cancer 0.93 (0.90-0.95) 3.0x10-8 0.82 
 
New association with ovarian cancer at a known index SNP 
for breast cancer (same direction) 
       
13q13 rs11571833d T/A Ovarian cancere 1.57 (1.33-1.85) 6.4x10-8 1f 
32972626 BRCA2 0.008 Breast cancere 1.46 (1.23-1.73) 6.9x10-6 1f 
  
New association with prostate cancer at a known index SNP 
for breast cancer (opposite direction) 
 
       
2q33 rs1830298 T/C Prostate cancer 1.06 (1.04-1.09) 1.3x10-6 0.99 
202181247 ALS2CR12 0.71 Breast cancer 0.94 (0.93-0.96) 2.6x10-10 0.99 
Abbreviations: (E/R), (effect/reference) alleles; EAF: effect allele frequency. 
 
aThe new associations are in bold text and listed first. 
bBuild 37 coordinates. 
cImputation accuracy, r2, in iCOGS European samples. 
dPreviously published genome-wide significant associations for rs6763931 (prostate cancer) and rs11571833 (breast cancer) did 
not reach P < 5 x 10-8 in the data sets used for the current study. 
eResults reported here are for ER-negative breast cancer and serous invasive ovarian cancer as the effect size estimates (odds 
ratios) were larger for the subtype-specific associations when compared to overall breast cancer and all invasive ovarian cancer. 
fGenotyped SNP. 
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Table 2. New cross-cancer loci identified at P < 10-8 that were over 1 Mb away from known index SNPs  
Region, Index SNP, (n), Alleles (E/R),       ASSET model,   
positiona nearest gene EAF Cancer Type OR (95% CI) P Phetb r2c 
A: From the three-cancer meta-analysis 
Associations with breast, ovarian and prostate cancer risk with the same direction of effect 
2q13 rs17041869 A/G Breast cancer 0.97 (0.94-0.99) 7.1x10-3 3-cancer 1d 
111896243 (3) 0.88 Ovarian cancer 0.93 (0.88-0.97) 5.3x10-4 0.07 1d 
 BCL2L11  Prostate cancer 0.92 (0.89-0.95) 2.6x10-6  1d 
   Meta-analysis 0.94 (0.93-0.96) 5.1x10-9   
11q12 rs7937840 T/C Breast cancer 1.04 (1.02-1.06) 3.6x10-5 3-cancer 0.89 
61893972 (1) 0.26 Ovarian cancer 1.05 (1.01-1.09) 5.8x10-3 0.95 0.90 
 INCENP  Prostate cancer 1.05 (1.02-1.08) 8.9x10-4  0.89 
   Meta-analysis 1.05 (1.03-1.06) 5.0x10-9   
19p13 rs1469713 A/G Breast cancer 0.95 (0.94-0.97) 9.9x10-8 3-cancer 0.98 
19528806 (89) 0.64 Ovarian cancer 0.96 (0.93-0.99) 6.3x10-3 0.64 0.98 
 GATAD2A  Prostate cancer 0.97 (0.94-0.99) 1.0x10-2  0.95 
   Meta-analysis 0.96 (0.95-0.97) 3.4x10-10   
B: From the pairwise meta-analyses 
Associations with breast and ovarian cancer risk with the same direction of effect 
9q31 rs200182588 G/GGC Breast cancer 0.96 (0.94-0.98) 1.9x10-5 2-cancer 0.81 
106856690 (15) 0.56 Ovarian cancer 0.93 (0.89-0.96) 2.8x10-6 0.08 0.82 
 SMC2  Meta-analysis 0.95 (0.94-0.97) 8.9x10-9   
15q26 rs8037137 T/C Breast cancer 1.07 (1.04-1.10) 1.8x10-7 2-cancer 0.98 
91506637 (33) 0.86 Ovarian cancer 1.09 (1.04-1.14) 2.1x10-4 0.58 0.98 
 RCCD1  Meta-analysis 1.07 (1.05-1.10) 9.1x10-10   
Associations with breast and prostate cancer risk with the same direction of effect 
1p34 rs5013329 T/C Breast cancer 1.04 (1.02-1.06) 7.8x10-6 2-cancer 0.98 
46815091 (218) 0.31 Prostate cancer 1.07 (1.04-1.10) 1.4x10-7 0.09 0.98 
 NSUN4  Meta-analysis 1.05 (1.04-1.07) 1.8x10-11   
6q23 rs9375701 T/C Breast cancer 1.04 (1.02-1.06) 3.6x10-6 2-cancer 0.99 
130384057 (53) 0.67 Prostate cancer 1.06 (1.03-1.08) 1.5x10-5 0.41 0.99 
  L3MBTL3    Meta-analysis 1.05 (1.03-1.06) 3.4x10-10     
Abbreviations: n, Number of SNPs with P < 10-8 within 1 Mb of the index SNP; (E/R), (effect/reference) alleles; EAF: effect allele 
frequency. 
 
aBuild 37 coordinates. 
bCochran's Q-test for heterogeneity P-value. 
cImputation accuracy, r2, in iCOGS European samples. 
dGenotyped SNP. 
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Figure Legends 
 
Figure 1. Manhattan plot of results from the combined breast, ovarian, and prostate cancer meta-analysis.  
The black and gray dots represent the 2,231 variants nominally associated (P < 0.05) with every cancer 
type individually that had the same direction of effect across all three cancers.  The red line corresponds 
to a threshold of P = 10-8.  Eighteen independent loci were identified at this threshold.  The green dots 
highlight index SNPs at 11 loci out of these 18 where model selection using ASSET confirmed 
contribution from all three cancer types to the association signal and that remained at P < 10-8 after 
adjusting for the controls shared between the breast and ovarian cancer studies.  Gene names identify the 
three loci out of the 11 that were > 1 Mb away from previously identified index SNPs for any of the three 
cancers. 
 
Figure 2. Forest plots of odds ratio estimates for the new cross-cancer index SNPs (> 1 Mb from known 
index SNPs) for susceptibility to (A) breast, ovarian, and prostate cancer and (B) breast and ovarian 
cancer, and breast and prostate cancer.  Error bars indicate 95% confidence intervals and het_P is the P-
value calculated from Cochran's Q-test for heterogeneity. 
 
Figure 3. Regional association plot of results from the three-cancer meta-analysis for the 
rs1469713/19p13 breast, ovarian, and prostate cancer susceptibility locus.  The black dots represent all 
variants nominally associated (P < 0.05) with every cancer type individually that had the same direction 
of effect across all three cancers.  The purple dashed line corresponds to a threshold of P = 10-8.  Tracks 
immediately below the regional association plot show the locations of enhancers in breast (pink), ovarian 
(green), and prostate (blue) cell types.  Interactions derived from ChIA-PET experiments, which have 
only been assayed in breast cells, are labeled as experimental interactions.  Where the same gene is 
predicted to be a target of enhancers that intersect with the same P < 10-8 SNP in all three cell types (or 
two for the 2q13 region), it is shown in red.  All other genes in the region are in gray.  The corresponding 
P < 10-8 SNP locations are marked by grey vertical stripes.  The lower tracks show arcs between 
enhancers and target genes for both computationally predicted and experimentally derived interactions.  
Arc colors reflect the cell type in which the enhancer-promoter pair was identified. 
 
Figure 4. Regional association plot of results from the three-cancer meta-analysis for the 
rs17041869/2q13 breast, ovarian, and prostate cancer susceptibility locus.  The black dots represent all 
variants nominally associated (P < 0.05) with every cancer type individually that had the same direction 
of effect across all three cancers.  The purple dashed line corresponds to a threshold of P = 10-8.  Tracks 
immediately below the regional association plot show the locations of enhancers in breast (pink), ovarian 
(green), and prostate (blue) cell types.  Interactions derived from ChIA-PET experiments, which have 
only been assayed in breast cells, are labeled as experimental interactions.  Where the same gene is 
predicted to be a target of enhancers that intersect with the same P < 10-8 SNP in all three cell types (or 
two for the 2q13 region), it is shown in red.  All other genes in the region are in gray.  The corresponding 
P < 10-8 SNP locations are marked by grey vertical stripes.  The lower tracks show arcs between 
enhancers and target genes for both computationally predicted and experimentally derived interactions.  
Arc colors reflect the cell type in which the enhancer-promoter pair was identified. 
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